Pharmaceutical Investing Minerva Neurosciences Appoints Dr. Inderjit Kaul to the Company's Board of Directors
Pharmaceutical Investing Minerva Neurosciences Reports Third Quarter 2025 Financial Results and Business Updates
Pharmaceutical Investing Minerva Neurosciences Announces Financing of up to $200 Million to Advance Roluperidone for the Treatment of Negative Symptoms in Patients with Schizophrenia Through a Phase 3 Confirmatory Trial and Resubmission of its New Drug Application and Preparation for US Commercial Launch, if Approved
Pharmaceutical Investing Minerva Neurosciences Provides Business Updates and Second Quarter Financial Results
Forge Resources Intersects 3.4 g/t Gold over 44.75 Metres, and 800 Metre Step-Out Discovers 1.04 g/t Gold over 55.52 Metres at Alotta, Yukon
